Technology ID
TAB-3739
Podocin Promoter, Reverse Tetracycline Transactivator Mice for Studying Podocyte Injury
E-Numbers
E-085-2014-0
Lead Inventor
Kopp, Jeffrey (NIDDK)
Applications
Therapeutics
Research Materials
Therapeutic Areas
Ophthalmology
Oncology
Infectious Disease
Endocrinology
Dental
Cardiology
Lead IC
NIDDK
ICs
NIDDK
This technology includes mice which are intended to be bred with mice that have the tetracycline-response element promoter driving a gene of interest, for the study of kidney diseases. When the dual transgenic mice are fed tetracycline or doxycycline, the transgene is activated in glomerular podocytes.
Commercial Applications
To study podocyte injury and repair in vivo.
Competitive Advantages
This approach provides podocyte-specific transgene expression.
Licensing Contact: